Release Date:  October 2, 1998

RFA:  HL-99-002


National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  December 1, 1998
Application Receipt Date:  January 13, 1999



This solicitation invites research grant applications focused on the role of
chemokines and chemokine receptors in the lungs, cardiovascular system and bone
marrow to elucidate virus-cell interactions in the pathogenesis of HIV in the
pulmonary, cardiovascular and hematopoietic systems.  An important aspect of this
RFA is to determine if chemokines or their derivatives can effectively block
infection of tissue macrophages and macrophage-lymphocyte transfer of virus. 
Another facet of the initiative is to determine if potential new antiviral
agents, based on the molecular interactions between chemokines, their receptors
and virus, block infection of cells in the lungs, cardiovasculature and bone
marrow or alter the evolution of virus in the involved organs.  Another crucial
question pertinent to this Request for Applications (RFA) is the developmental
timing of vulnerability to infection by cells, especially, in the bone marrow. 
Human studies, e.g., in subjects with various chemokine receptor phenotypes, or
with varying stages of HIV infection as compared to healthy persons, and studies
in animal models would be of interest.  Among the disciplines and expertise that
may be appropriate for this research program are immunology, molecular
immunology, cell biology, molecular biology, virology, genetics, infectious
diseases, pathology, pulmonology, cardiology, hematology, and mathematical


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This RFA, HIV in the Lungs, Heart, and
Blood:  Role of Chemokines and Their Receptors, is related to the priority areas
of HIV infection and immunization and infectious diseases.  Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report:  Stock
No.017-001-00474-0 or Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325 (telephone 202-512-1800).


Applications may be submitted by domestic and foreign, for-profit and non-profit
organizations, public and private, such as universities, colleges, hospitals,
laboratories, units of State or local governments, and eligible agencies of the
Federal government.  Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.  All current
policies and requirements that govern the research grant programs of the National
Institutes of Health (NIH) will apply to grants awarded under this RFA.  Awards
under this RFA to foreign institutions will be made only for research of very
unusual merit, need, and promise, and in accordance with PHS policy governing
such awards.


This RFA will use the NIH individual research project grant (R01) mechanism of
support.  Investigators without prior R29 or R01 support are encouraged to apply
for this RFA and to identify their status on the front of the grant application. 
Specific R01 application instructions have been modified to reflect "MODULAR
GRANT" and "JUST-IN-TIME" streamlining efforts being examined by the NIH.  The
modular grant concept establishes specific modules in which direct costs may be
requested as well as a maximum level for requested budgets.  Only limited
budgetary information is required under this approach.  The just-in-time concept
allows applicants to submit certain information only when there is a possibility
for an award.  It is anticipated that these changes will reduce the
administrative burden for the applicants, applicant institutions, reviewers, and
Institute staff.  Although multidisciplinary approaches are encouraged, it is not
the intent of this RFA to solicit applications for large studies encompassing a
variety of individual subprojects, i.e., program projects.  If collaborative
arrangements through subcontracts with other institutions are planned, consult
the program staff listed under INQUIRIES.

For this RFA, funds must be requested in $25,000 direct cost modules and a
maximum of eight modules ($200,000 direct costs) per year may be requested.  A
feature of the modular grant concept is that no escalation is provided for future
years, and all anticipated expenses for all years of the project must be included
within the number of modules being requested.  Only limited budgetary information
will be required and any budget adjustments made by the Initial Review Group will
be in modules of $25,000.  Instructions for completing the Biographical Sketch
have also been modified.  In addition, Other Support information and the
application Checklist page are not required as part of the initial application. 
If there is a possibility for an award, necessary budget, Other Support and
Checklist information will be requested by NHLBI staff following the initial

The APPLICATION PROCEDURES section of this RFA provides specific details of
modifications to standard PHS 398 application kit instructions.  Applicants are
expected to furnish their own estimates of time required to achieve the
objectives of the proposed research project.  Since a variety of approaches would
represent valid responses to this RFA, it is anticipated that there will be a
range of costs among individual grants awarded.  Up to 5 years of support may be
requested on R01 applications.

This RFA is a one-time solicitation.  Future unsolicited competing continuation
applications will compete with all investigator-initiated applications and be
reviewed according to the customary peer review procedures.  It is anticipated
that support for this program will begin in July 1999.  Administrative
adjustments in project period and/or amount may be required at the time of the

Applicants from institutions that have a General Clinical Research Center (GCRC)
funded by the NIH National Center for Research Resources may wish to identify the
GCRC as a resource for conducting the proposed research.  If so, a letter of
agreement from either the GCRC program director or principal investigator should
be included with the application.

The National Institute of Allergy and Infectious Diseases (NIAID) has interest
in understanding how chemokines and chemokine receptors affect the pathogenesis
of HIV disease.  Therefore, applications that are of mutual interest are likely
to be given a secondary assignment to NIAID in accordance with the NIH referral


It is anticipated that for fiscal year 1999, approximately $4,000,000 total costs
will be available for the first year of support for this initiative.  Award of
grants pursuant to this RFA is contingent upon receipt of such funds for this
purpose.  It is anticipated that approximately 15 new grants will be awarded
under this program.  The specific number to be funded will, however, depend on
the merit and scope of the applications received and on the availability of
funds.  Direct costs will be awarded in modules of $25,000, less any overlap or
other necessary administrative adjustments. Indirect costs will be awarded based
on the negotiated rates.  Applicants may request up to 5 years of support.



Two years ago a second receptor for HIV, CCR5, was discovered that helps explain
why some individuals are apparently resistant to HIV infection despite continued
exposure to the virus, and why some individuals with infection do not develop
overt clinical symptoms.  People unable to make normal CCR5 were found to be
resistant to infection when exposed to HIV.  These people carry a mutation of
CCR5 (the CCR5รพ32 deletion) that makes the receptor non-functional, therefore not
allowing certain strains of the HIV virus to enter their cells.  Presumably,
because the abnormal CCR5 chemokine receptor is unable to bind to HIV-1 gp120. 
Heterozygosity for the CCR5 mutation was observed to slow the progression of HIV
disease in a study of infected infants.  However, the risk of mother-to-infant
transmission in these infants with one copy of the mutant CCR5 receptor did not
appear to be reduced.

Other studies have revealed that CCR5 is also the receptor for chemokines that
blocks HIV infection.  A derivative of RANTES (regulated on activation, normal
T cell expressed and secreted), one of the chemokines that binds to CCR5, has
been produced.  Unlike the parent molecule, the derivative cannot attract and
activate cells that participate in inflammatory reactions and immune defenses,
but it can block binding of HIV to CCR5 and other similar receptors.  Such an
agent has the potential of acting as an anti-viral substance and opens up the
possibility of developing new classes of anti-HIV drugs.

It is also clear that CCR5 is not the only coreceptor; many others probably
exist.  Some HIV viruses have already been found that can use other chemokine
receptor molecules in addition to CCR5.  Thus far, at least thirteen of them,
such as CXCR4, CCR2b and CCR3 have been identified and more receptors are likely
to emerge.  As yet, little is known concerning the identity of the cells carrying
these receptors and in what tissues these other receptor molecules are expressed. 
It is likely that cells in different tissues express different receptors. 
Because HIV seems to evolve independently in specific organs, particularly in the
lung and brain, it is important to learn more about their function.

Although the lung is still the major organ affected by opportunistic infection,
the role of chemokines in modulating the expression of HIV in the lung has
received little attention. This program would support research on the chemokine
receptors and cofactors expressed in cells in the lung from HIV infected persons
as well as in animal models.  Although a great deal of chemokine receptor work
is being performed on tissue other than the lung, little work is currently being
done on the tissue most often affected by opportunistic infection.  Studies would
require access to BAL specimens and possibly to animal models.  It is likely that
new animal models will soon be available, based on the discovery of the HIV
coreceptors, such as transgenics expressing human CD4 along with cofactors.  It
may be possible to use such new models in the lung to address the pathogenesis
of HIV at the end organ level to see how this affects the establishment of
altered immunity in the lung, the development of tuberculosis, opportunistic
infections and cellular infiltrates associated with HIV.

The role of HIV infection in the development of cardiovascular complications has
only recently been recognized.  The mechanisms for HIV-1 related cardiovascular
complications may derive from direct infection of the myocytes and endothelial
cells, or may be due to indirect, secondary effects of viral infection mediated
by monocytes and macrophages and other inflammatory mediators.  At present 
little is known about the pathogenesis of cardiovascular disease associated with
HIV-1 infection.

Recently, results of mice lacking PBSF/SDF-1 (for pre-B-cell growth-stimulating
factor/stroma-cell-derived factor), a CXC chemokine, indicate that PBSF/SDF-1 is
essential for viability of the embryo, B lymphopoiesis, bone marrow myelopoiesis,
and cardiac ventricular septum formation.  CXCR4, a receptor for PBSF/SDF-1 and
HIV, is expressed in cells of both the immune and the central nervous systems,
and in developing vascular endothelial cells.  Mice lacking CXCR4 exhibit
hematopoietic and cardiac defects identical to those of PBSF/SDF-1-deficient
mice, and they also have defective vascular development.  Examples of chemokine
receptors and chemokines expressed in the heart and lung include a human
receptor-HCR, a rat chemoattractant-like receptor, a murine MIP-1 alpha receptor,
MCP-4 and human MCP-2.

Circulating levels of C-C chemokines (MCP-1, MIP-1 alpha, and RANTES) have been
reported to be increased in congestive heart failure, with particularly high
levels measured in patients with severe disease.  Platelet factor 4 (PF-4), an
archetype of the "chemokine" family, acts as a potent inhibitor of endothelial
cell proliferation.  Chemokines have also been implicated in the pathogenesis of
atherosclerosis.  RANTES mRNA and protein were detected in endothelial cells of
arteries undergoing accelerated atherosclerosis, but not in normal coronary
arteries.  RANTES is proposed to be a pivotal mediator of the cellular infiltrate
seen in graft atherosclerosis.  Mice with the selective absence of CCR2, the
receptor for MCP-1, have decreased lesion formation, markedly decreased in
apoE-/- mice.  These data suggest a role for chemokines, particularly MCP-1, in
the development of early atherosclerotic lesions.

While the expression and function of some chemokines and chemokine receptors have
been implicated in the cardiovascular system in the absence of HIV infection,
information is lacking on the role and the expression of chemokines and chemokine
receptors in the cardiovasculature in the setting of HIV-1 infection.  How these
factors may relate to the prevention or enhancement of HIV infection in
cardiovascular system and the progression of cardiovascular complications is
unclear.  More accurate assessment of the impact of immunity, chemokine and
chemokine receptor expression, viral infection, and genetic mutations upon
cardiovascular structure and function is required.

The role of chemokines in HIV-associated hematopoietic suppression needs to be
elucidated.  This might include how the chemokines and their receptors function
in mediating HIV-associated cell injury and death in the bone marrow.  Chemokines
may also alter cell ontogeny such that there are critical times of vulnerability
for HIV access and integration into the cell.

Objectives and Scope

The objective of this program is to learn more about the role of chemokines and
chemokine receptors in the pathogenesis of HIV in the lungs, the cardiovascular
system, and bone marrow.  Whether chemokines, chemokine derivatives or potential
antiviral agents based on chemokine-chemokine receptor-viral interactions block
the entry of HIV into tissue macrophages and alter the course of infection in
these and other cells in the lungs, cardiovascular system, and bone marrow is of
particular interest.

Examples of areas of research (in HIV-infected, other immunodeficient or "normal"
human subjects, suitable animal models, in vitro models, or non-linear
mathematical models) that might be included under this RFA are as follows:

In new animal models based on the discovery of the HIV coreceptors, address
mechanisms relevant to the pathogenesis of HIV at the end organ level.  This
might include studying various aspects of immune dysfunction in the lungs,
cardiovascular system, or bone marrow that are pertinent to HIV's secondary
consequences such as tuberculosis, opportunistic infections or pulmonary
infiltrates, cardiomyopathy, endothelial dysfunction and suppression of

Examine questions relating to the distribution of receptors and how they
determine cell-specific permissiveness to HIV infection.  The production,
accumulation, and role of chemokines in regulating virus replication in the
lungs, cardiovascular system, and bone marrow could also be addressed.

Further identify and characterize chemokines which serve as hematopoietic
suppressors in HIV infected patients with an emphasis on reversal of the

Study the role of chemokines in hematopoietic and immune function in HIV infected

Study the ontogeny of stem cells to mature cells that delineate the chemokine
receptor developmental process with emphasis on the timing of vulnerability to
HIV infection.

Elucidate signal transduction mechanisms involved in the interplay of chemokines
and their receptors which may influence viral-associated cytopathicity or
apoptotic responses in the marrow, lungs or cardiovascular system.

Study the expression of chemokines and chemokine receptors in the heart during
HIV-1 infection.  Determine how these factors may relate to the progression of
cardiovascular complications.

Assess the impact of immunity, chemokine and chemokine receptor expression, viral
infection, and genetic mutations upon lung, cardiovascular, and bone marrow
structure and function.

These are examples only.  Investigators should not feel limited to the subjects
mentioned above and are encouraged to submit other topics pertinent to the
objectives of the RFA.  Individual applications may address lung, cardiovascular
system, or bone marrow research.  It is not necessary for any one project to
address issues related to all three.

It is anticipated that human, animal, in vitro studies and studies that include
non-linear mathematical models would be appropriate. Investigators are encouraged
to apply findings from theoretical and in vitro work to in vivo studies when this
is feasible.  The initiative is relevant to black and Hispanic minority
populations who are disproportionately affected by HIV in comparison to the total


Upon initiation of the program, the NHLBI will sponsor periodic meetings to
encourage exchange of information among investigators who participate in this
program.  In the budget of the grant application, travel funds for a one day
meeting each year, most likely to be held in Bethesda, Maryland, should be
included in the modules.  Applicants should also include a statement in their
applications indicating their willingness to participate in these meetings.

Applications that focus exclusively on normal chemokine and chemokine receptor
function in the lungs, cardiovascular system, and bone marrow are not acceptable. 
However, studies of normal chemokine and chemokine receptor function may be
included, for comparison purposes, along with studies of HIV infection,
appropriate models of HIV infection, HIV-associated abnormalities of function,
HIV-associated opportunistic infections and complications.  Applications that
propose descriptive studies and do not contain hypothesis driven studies directed
at understanding the mechanisms of chemokine, chemokine receptor and viral
interactions, will not be acceptable.  Applications that focus on molecular
mechanisms are of particular interest.  Although studies in human subjects are
strongly encouraged, large clinical studies are not within the scope of this RFA. 
Applicants who propose to test hypotheses in animal, in vitro models or
theoretical models must provide a strong rationale for relevance to the human
host.  This program will not support studies directed at development of animal
models alone.  Therefore, models must be applied to the study of role chemokines
and/or chemokine receptors in the lungs, cardiovascular system, or bone marrow
in HIV-infection or in other infections and immunodeficient states relevant to
elucidating dysfunction in HIV-infection.


It is the policy of the NIH that women and members of minority groups and their
subpopulations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear and compelling
rationale and justification is provided that inclusion is inappropriate with
respect to the health of the subjects or the purpose of the research.  This
policy results from the NIH Revitalization Act of 1993 (Section 492B of Public
Law 103-43).

All investigators proposing research involving human subjects should follow the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research", which have been published in the Federal Register of March 28, 1994
(FR 59 14508-14513), and in the NIH Guide for Grants and Contracts, Vol. 23, No.
11, March 18, 1994.

Investigators also may obtain copies of the policy from the program staff listed
under INQUIRIES.  Program staff may also provide additional relevant information
concerning the policy.


It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them.  This
policy applies to all initial (Type 1) applications submitted for receipt dates
after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for Grants
and Contracts, March 6, 1998, and is available at the following URL address:


Prospective applicants are asked to submit, by December 1, 1998, a letter of
intent that includes a descriptive title of the proposed research, the name,
address, and telephone number of the Principal Investigator, the identities of
other key personnel and participating institutions, and the number and title of
the RFA in response to which the application may be submitted.  If the applicant
is a new investigator (i.e., an investigator without prior R29 or R01 support),
you may wish to take the opportunity to identify yourself as such in the letter
of intent as well as on the cover page of the application.  Although a letter of
intent is not required, is not binding, and does not enter into the review of
subsequent applications, the information that it contains allows NHLBI staff to
estimate the potential review workload and to avoid conflict of interest in the

The letter of intent is to be faxed or sent to Dr. C. James Scheirer, at the
address listed under INQUIRIES.


The research grant application form PHS 398 (rev. 5/95) is to be used in applying
for these grants.  Application kits are available at most institutional offices
of sponsored research and may be obtained from the Division of Extramural
Outreach and Information Resources, National Institutes of Health, 6701 Rockledge
Drive, MSC 7910, Bethesda, MD 20898-7910, telephone 301-710-0267, Email:

The RFA label found in the PHS 398 application form must be affixed to the bottom
of the face page of the application.  Failure to use this label could result in
delayed processing of the application such that it may not reach the review
committee in time for review.  In addition, the RFA title and number must be
typed on line 2 of the face page of the application form and the "YES" box must
be marked.

This RFA is restricted to R01 grants.  All will be awarded as modular grants. 
The modular grant concept establishes specific modules (increments) in which
direct costs may be requested and a maximum level for requested direct cost. 
Only limited budgetary information is required in the application; a detailed
budget need not be provided.

Sample budgets and justification page will be provided upon request, from Mr.
Raymond Zimmerman at the address listed under INQUIRIES or following the
submission of a letter of intent.

The total direct costs must be requested in accordance with the program
guidelines and the modifications made to the standard PHS 398 application
instructions described below:

As a reminder, Item 7 should be completed to indicate Modular Direct Costs
requested and Item 8 should reflect Total Costs (Modular Direct plus F&A costs).

Do not complete Form Page 4 of the PHS 398 (rev 5/95).  It is not required nor
will it be accepted at the time of application.

Do not complete the categorical budget tables on Form page 5 of the PHS 398 (rev.
5/95). Only the requested total direct costs line for each year must be completed
based on the number of $25,000 modules being requested.  Applicants may not
request a change in the amount of each module.  A maximum of EIGHT modules
($200,000 direct costs) per year may be requested and each applicant may request
up to FIVE years of support for this RFA.  Direct cost budgets will remain
constant throughout the life of the project (i.e., the same number of modules
requested for all budget periods).  Any necessary escalation should be considered
when determining the number of modules to be requested.  However, in the event
that the number of modules requested must change in any future year due to the
nature of the research proposed, appropriate justification must be provided. 
Total Direct Costs for the Entire Proposed Project Period should be shown in the
box provided.


-  Budget justifications should be provided under "Justifications" on Form Page
5 of the PHS 398.

-  List the names, role on the project and proposed percent effort for all
project personnel (salaried or unsalaried) and provide a narrative justification
for each person based on his/her role on the project.  UNDER THE JUSTIFICATION

-  Identify all consultants by name and organizational affiliation and describe
the services to be performed.

-  Provide a general narrative justification for individual categories
(equipment, supplies, etc.) required to complete the work proposed.  More
detailed justifications should be provided for high cost items.  Any large
one-time purchases, such as large equipment requests, must be accommodated within
these limits.  No specific costs for items or categories should be shown.

o  CONSORTIUM/CONTRACTUAL COSTS - If collaborations or subcontracts are involved
that require transfer of funds from the grantee to other institutions, it is
necessary to establish formal subcontract agreements with each collaborating
institution.  A letter of intent from each collaborating institution should be
submitted with the application.  Only the percentage of the
consortium/contractual TOTAL COSTS (direct and indirect) relative to the total
DIRECT COSTS of the overall project needs to be stated at this time. The
following example should be used to indicate the percentage cost of the
consortium, "The consortium agreement represents 27% of overall $175,000 direct
costs requested in the first year."  A budget justification for the consortium
should be provided as described in the "Budget Justification" section above (no
Form Page 5 required for the consortium).  Please indicate whether the consortium
will be in place for the entire project period and identify any future year
changes in the percentage relative to the parent grant.

If there is a possibility for an award, the applicant will be requested to
identify actual direct and indirect costs for all years of the consortium. Please
note that total subcontract costs need not be calculated in $25,000 modules. 
However, when subcontract funds are added to the parent grant budget, the total
direct cost amount must be included in the number of $25,000 modules requested.

o  BIOGRAPHICAL SKETCH - A biographical sketch is required for all key personnel,
following the modified instructions below.  Do not exceed the two-page limit for
each person.

-  Complete the education block at the top of the form page;

-  List current position(s) and those previous positions directly relevant to the

-  List selected peer-reviewed publications directly relevant to the proposed
project, with full citation;

-  The applicant has the option to provide information on research projects
completed and/or research grants participated in during the last five years that
are relevant to the proposed project.

o  OTHER SUPPORT - Do not complete the "Other Support" pages (Form Page 7). 
Selected other support information relevant to the proposed research may be
included in the Biographical Sketch as indicated above. Complete Other Support
information will be requested by NHLBI staff if there is a possibility for an

o  CHECKLIST - No "Checklist" page is required as part of the initial
application.  A completed Checklist will be requested by NHLBI staff if there is
a possibility for an award.

o  The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information is
necessary following the initial review.


Submit a signed, typewritten original of the application and three signed,
photocopies, in one package to:

6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)

At the time of submission, two additional copies of the application must be sent
to Dr. C. James Scheirer at the listed under INQUIRIES.

Applications must be received by January 13, 1999.  If an application is received
after that date, it will be returned to the applicant without review. The Center
for Scientific Review (CSR) will not accept any application in response to this
RFA that is essentially the same as one currently pending initial review, unless
the applicant withdraws the pending application.  The CSR will not accept any
application that is essentially the same as one already reviewed.  This does not
preclude the submission of substantial revisions of applications already
reviewed, but such applications must include an introduction addressing the
previous critique.


Applications will be reviewed for completeness by the CSR and for responsiveness
by NHLBI.  Incomplete and/or unresponsive applications will be returned to the
applicant without further consideration.  Applications that are complete and
responsive to the RFA will be evaluated for scientific and technical merit by an
appropriate peer review group convened by the NHLBI, in accordance with NIH peer
review procedures.  As part of the initial merit review, all applications will
receive a written critique and undergo a review in which only those applications
deemed to have the highest scientific merit of the applications under review
(usually two to three times the number of applications that the NHLBI anticipates
being able to fund under the program) will be discussed, assigned a priority
score, and receive a second level review by the National Heart, Lung, and Blood
Advisory Council.

The personnel category will be reviewed for appropriate staffing based on the
requested percent effort and justification provided.  The direct costs budget
request will be reviewed for consistency with the proposed methods and specific
aims.  Any budgetary adjustments recommended by the reviewers will be in $25,000
modules.  The duration of support will be reviewed to determine if it is
appropriate to ensure successful completion of the requested scope of the

Review Criteria

The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health.  In the
written review, comments on the following aspects of the application will be made
in order to judge the likelihood that the proposed research will have a
substantial impact on the pursuit of these goals.  Each of these criteria will
be addressed and considered in the assignment of the overall score.

(1) Significance

Does this study address an important problem?  If the aims of the application are
achieved, how will scientific knowledge be advanced? What will be the effect of
these studies on the concepts or methods that drive this field?

(2) Approach

Are the conceptual framework, design, methods, and analyses adequately developed,
well-integrated, and appropriate to the aims of the project?  Does the applicant
acknowledge potential problem areas and consider alternative tactics?

(3) Innovation

Does the project employ novel concepts, approaches or method?  Are the aims
original and innovative?  Does the project challenge existing paradigms or
develop new methodologies or technologies?

(4) Investigator

Is the investigator appropriately trained and well suited to carry out this work? 
Is the work proposed appropriate to the experience level of the principal
investigator and other researchers (if any)?

(5) Environment

Does the scientific environment in which the work will be done contribute to the
probability of success?  Do the proposed experiments take advantage of unique
features of the scientific environment or employ useful collaborative
arrangements?  Is there evidence of institutional support?

In addition, the adequacy of plans to include both genders and minorities and
their subgroups as appropriate for the scientific goals of the research will be
reviewed.  Plans for the recruitment and retention of subjects will also be

The initial review group will also examine the provisions for the protection of
human and animal subjects, the safety of the research environment, and
conformance with the NIH Guidelines for the Inclusion of Women and Minorities as
Subjects in Clinical Research.

The roster of the initial review group will be available, via the NHLBI homepage.


The following will be considered in making funding decisions: quality of the
proposed project as determined by peer review, availability of funds, and program
priority.  Applications from new investigators will be strongly considered.

The anticipated date of award is July 1, 1999


Inquiries concerning this RFA are encouraged.  The opportunity to clarify any
issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Hannah H. Peavy, M.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 10018, MSC 7952
Bethesda, MD  20892-7952
Telephone:  (301) 435-0222
FAX:  (301) 480-3557

Dr. Lan-Hsiang Wang
Division of Heart and Vascular Disease
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 9044, MSC 7940
Bethesda, MD  20892-7940
Telephone:  (301) 435-0510
FAX:  (301) 480-1335

Dr. Carol Letendre
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 10042, MSC 7950
Bethesda, MD  20892-7950
Telephone:  (301) 435-0080
FAX:  (301) 480-0867

Direct inquiries regarding fiscal matters (e.g. sample budget pages) to:

Raymond L. Zimmerman
Grants Operations Branch Division of Extramural Affairs
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Suite 7154, MSC 7926
Bethesda, MD  20892-7926
Telephone:  (301) 435-0171
FAX:  (301) 480-3310

Inquires regarding review, letters of intent and two copies of the grant
application should be directed to:

C. James Scheirer, Ph.D.
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
6701 Rockledge Drive, Room 7220, MSC 7924
Bethesda, MD  20892-7924
Telephone:  (301) 435-0266
FAX:  (301) 480-3541


This program is described in the Catalog of Federal Domestic Assistance, No.
93.838.  Awards are made under authorization of the Public Health Service Act,
Title IV, Part A (Public Law 78-410, amended by Public Law 99-158, 42 U.S.C. 241
and 285) and administered under PHS grants policies and Federal Regulations 42
CFR 52 and 45 CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or a Health Systems Agency Review.

The PHS strongly encourages all grant and contract recipients to provide a
smoke-free workplace and promote the non-use of all tobacco products. In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which regular
or routine education, library, day care, health care or early childhood
development services are provided to children.  This is consistent with the PHS
mission to protect and advance the physical and mental health of the American

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.